BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12099518)

  • 1. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.
    Internation Neoral Renal Transplantation Study Group
    Am J Transplant; 2002 Feb; 2(2):157-66. PubMed ID: 12099518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation.
    International Neoral Renal Transplantation Study Group.
    Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab widens the therapeutic window for AUC-monitored neoral therapy early after kidney transplantation.
    Balbontin F; Kiberd B; Singh D; Squires J; Fraser A; Belitsky P; Lawen J
    Transplant Proc; 2003 Nov; 35(7):2409-11. PubMed ID: 14611972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.
    Trompeter R; Fitzpatrick M; Hutchinson C; Johnston A
    Pediatr Transplant; 2003 Aug; 7(4):282-8. PubMed ID: 12890006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
    Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
    Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
    Mahalati K; Belitsky P; Sketris I; West K; Panek R
    Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems of cyclosporine absorption profiling using C2-monitoring.
    Schuetz M; Einecke G; Mai I; Neumayer HH; Glander P; Waiser J; Fritsche L; Budde K
    Eur J Med Res; 2005 Apr; 10(4):175-8. PubMed ID: 15946914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients.
    Solari SG; Goldberg LR; DeNofrio D; Shaw LM
    Ther Drug Monit; 2005 Aug; 27(4):417-21. PubMed ID: 16044096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.
    Balbontin F; Kiberd B; Fraser A; Kiberd M; Lawen J
    Clin Transplant; 2005 Apr; 19(2):225-9. PubMed ID: 15740559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection.
    Balshaw R; Machnicki G; Carreño CA; Toselli L; Otero A; Keown PA
    Transplant Proc; 2005 Mar; 37(2):871-4. PubMed ID: 15848560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month.
    Morris RG; Russ GR; Cervelli MJ; Juneja R; McDonald SP; Mathew TH
    Ther Drug Monit; 2002 Aug; 24(4):479-86. PubMed ID: 12142630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
    Cole E; Deshpande R
    Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.
    Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffery J; Russell D; Stiller C; Muirhead N; Cole E; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P
    Transplantation; 1996 Dec; 62(12):1744-52. PubMed ID: 8990355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.